Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Drug-coated balloon shows superiority in coronary in-stent restenosis treatment March 11, 2024 Eating more fiber supports growth of good bacteria and protects against gut infections January 10, 2025 SARS-CoV-2 fragments found to mimic immune system peptides, fueling inflammation February 5, 2024
Eating more fiber supports growth of good bacteria and protects against gut infections January 10, 2025